AffaMed Therapeutics
Privately held: no public share price · China
Assets
(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Glucocorticoid receptorSmall molecule | Allergic ConjunctivitisOcular Inflammation Ocular Inflammation and Pain | |
| Phase 3 | Nasal chemosensory receptorsSmall molecule | Social Anxiety Disorder |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
6 August 2026Topline resultfasedienolExploratory Phase 2 repeat-dose study of fasedienol: primary endpoint not statistically significant
VistaGen Therapeutics · Source ↗
30 June 2026Topline resultfasedienolPhase 3 PALISADE-4 of fasedienol did not meet its primary endpoint
VistaGen Therapeutics · Source ↗
Financial reports
No financial reports recorded.